Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

Roche’s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals

Roche's Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals